SetPoint Medical’s neuroimmune modulation platform has been granted with the US FDA’s Breakthrough Device Designation for treating relapsing-remitting multiple sclerosis (RRMS). The device also received the US FDA’s BDD in 2020 to treat rheumatoid arthritis (RA)
The company is also investigating its platform technology under the (RESET-RA) clinical program for the treatment of moderate-to-severe RA adults
The neurostimulation device works by placing it surgically on the vagus nerve. It stimulates the vagus nerve (once daily) to deliver therapy and activate the inflammatory reflex for a systemic immune-restorative effect
Ref: SetPoint Medical | Image: SetPoint Medical
Related News:- Kyverna Therapeutics Enters into a Collaboration Agreement with Stanford University to Evaluate KYV-101 for the Treatment of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
